ArticleThe journal of nutrition, health & aging2025
Plasma biomarkers for monitoring muscle function and physical performance decline in older adults: A 2-year longitudinal study.
Article in The journal of nutrition, health & aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Myokines in exercise‑mediated bone homeostasis: Molecular signaling mechanisms and therapeutic implications for bone disorders (Review).International journal of molecular medicine · 2026Review
- Novel biomarkers for sarcopenia: a narrative review.Journal of orthopaedic surgery and research · 2026Review
- Distinct Proteomic Signatures Driving Progression of Sarcopenia: A Longitudinal Multicohort Study.Journal of cachexia, sarcopenia and muscle · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReliable biomarkers for diagnosing and monitoring sarcopenia remain limited, especially those reflecting longitudinal changes in muscle health. This study aimed to evaluate associations between plasma biomarkers and both cross-sectional and 2-year longitudinal changes in muscle mass, strength, and physical performance in older adults.
methodsWe analyzed plasma biomarkers in 93 participants (mean age: 74.3 years; 88% female) from a hospital-based longitudinal cohort. Biomarkers were quantified using ELISA, and multivariable regression analyses were conducted for sarcopenia components such as muscle mass, function, and performance, adjusting for age, sex, and body mass index (BMI).
resultsLeptin levels were negatively associated with both baseline and 2-year changes in appendicular lean mass indexed by ALM/height
conclusionThese findings highlight the potential of specific plasma biomarkers to identify individuals at risk of sarcopenia-related functional decline and to serve as practical tools for monitoring sarcopenia progression in older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.